Literature DB >> 10899435

Properties of NACP/alpha-synuclein and its role in Alzheimer's disease.

A Iwai1.   

Abstract

The precursor of the non-amyloid beta/A4 protein (non-Abeta) component of Alzheimer's disease amyloid (NACP)/alpha-synuclein is the human homologue of alpha-synuclein, a member of a protein family which includes alpha-, beta- and gamma-synuclein. This protein is thought to be involved in neuronal plasticity because of its unique expression, mainly in the telencephalon during maturation. Consequently, disarrangement of NACP/alpha-synuclein might disrupt synaptic activity, resulting in memory disturbance. Previous studies have shown that damage to synaptic terminals is closely associated with global cognitive impairment and is an early event in the pathogenesis of Alzheimer's disease. Although the relationship between synaptic damage and amyloidogenesis is not clear, some proteins at the synaptic site have been implicated in both neuronal alteration and amyloid formation. Indeed, abnormal accumulation of both NACP/alpha-synuclein and Abeta precursor protein occurs at synapses of Alzheimer's patients. Other evidence suggests that NACP/alpha-synuclein is a component of the Lewy bodies found in patients with Parkinson's disease or dementia with Lewy bodies, and that a point mutation in this protein may be the cause of familial Parkinson's disease. Consequently, abnormal transport, metabolism or function of NACP/alpha-synuclein appears to impair synaptic function, which induces, at least in part, neuronal degeneration in several neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899435     DOI: 10.1016/s0925-4439(00)00036-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  33 in total

Review 1.  Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.

Authors:  Dena A M Amer; G Brent Irvine; Omar M A El-Agnaf
Journal:  Exp Brain Res       Date:  2006-05-30       Impact factor: 1.972

Review 2.  Synaptic protein alterations in Parkinson's disease.

Authors:  Ilse S Pienaar; David Burn; Christopher Morris; David Dexter
Journal:  Mol Neurobiol       Date:  2011-12-29       Impact factor: 5.590

Review 3.  The Role of alpha-synuclein assembly and metabolism in the pathogenesis of Lewy body disease.

Authors:  Makoto Hashimoto; Kohichi Kawahara; Pazit Bar-On; Edward Rockenstein; Leslie Crews; Eliezer Masliah
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 4.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 5.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

6.  Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model.

Authors:  Min S Wang; Shanta Boddapati; Sharareh Emadi; Michael R Sierks
Journal:  BMC Neurosci       Date:  2010-04-30       Impact factor: 3.288

7.  Annexin A5 directly interacts with amyloidogenic proteins and reduces their toxicity.

Authors:  Sahar Bedrood; Sajith Jayasinghe; Derek Sieburth; Min Chen; Saskia Erbel; Peter C Butler; Ralf Langen; Robert A Ritzel
Journal:  Biochemistry       Date:  2009-11-10       Impact factor: 3.162

8.  Establishment of stably transfected rat neuronal cell lines expressing alpha-synuclein GFP fusion proteins.

Authors:  Gert Schwach; Michaela Tschemmernegg; Roswitha Pfragner; Elisabeth Ingolic; Edith Schreiner; Manfred Windisch
Journal:  J Mol Neurosci       Date:  2009-10-09       Impact factor: 3.444

9.  Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.

Authors:  Dora Games; Elvira Valera; Brian Spencer; Edward Rockenstein; Michael Mante; Anthony Adame; Christina Patrick; Kiren Ubhi; Silke Nuber; Patricia Sacayon; Wagner Zago; Peter Seubert; Robin Barbour; Dale Schenk; Eliezer Masliah
Journal:  J Neurosci       Date:  2014-07-09       Impact factor: 6.167

10.  Role of synucleins in Alzheimer's disease.

Authors:  Leslie Crews; Igor Tsigelny; Makoto Hashimoto; Eliezer Masliah
Journal:  Neurotox Res       Date:  2009-06-24       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.